However, it is essential to take into account that BBB-crossing ARBs (e.g., telmisartan, candesartan) or ACE inhibitors (e.g., captopril, lisinopril, fosinopril, perindopril, ramipril, trandolapril) (Glodzik and Santisteban, 2021) may show better results in neurologic, cognitive and memory impairments caused by COVID-19. The gene discussed is ACE; the disease is COVID-19.